Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554992 | 0.84 | DPP4 (0.34) | — | |
| SCHEMBL2595112 | 0.71 | MAPK8 (0.40) | OPRM1OPRK1POLBGAA | |
| SCHEMBL5009716 | 0.69 | OPRM1 (0.38) | OPRM1OPRK1POLBGAA | |
| SCHEMBL14730133 | 0.68 | SCN9A (0.38) | — | |
| Hydrochloric Acid SCHEMBL30785586 | 0.68 | OPRM1 (0.38) | OPRM1OPRK1POLBGAA | |
| Hydrochloric Acid SCHEMBL5012186 | 0.68 | OPRM1 (0.38) | OPRM1OPRK1POLBGAA | |
| SCHEMBL17221283 | 0.68 | NOS3 (0.36) | POLB | |
| SCHEMBL554729 | 0.68 | KDM4E (0.36) | — | |
| SCHEMBL2593658 | 0.67 | PDE4A (0.34) | POLBGAA | |
| SCHEMBL9887464 | 0.67 | KDM4A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | disclosed |
| US-20150126522-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | OPRM1 960/4885OPRK1 225/4885POLB 2211/4885 |
| US-20150126522-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | OPRM1 4740/4885OPRK1 4641/4885POLB 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.